Arrhythmias & electrophysiology
Anticoagulant in atrial fibrillation patients with prior intracranial haemorrhage: a meta-analysis
Pooled result · ICH recurrenceResult — go to the resultHazard ratio 0.85 95% CI 0.57–1.25Authors' conclusion
For patients with AF with prior ICH, OAC is associated with a significant reduction in IS/SE and all-cause mortality without increasing ICH recurrence, but may increase major bleeding risk. Compared with warfarin, NOACs had a better safety profile and comparable efficacy.
Study context
- Population
- Atrial fibrillation (AF) patients with prior intracranial haemorrhage (ICH)13 articles (11 real-world studies, 2 randomised controlled trials (RCTs))
- Participants
- 17,600 patients
- Comparison
- Oral anticoagulation (OAC) vs no anticoagulants; NOACs vs warfarin
Methodological detailsSearched PubMed, Embase, Web of Science and Cochrane Library to 13 February 2022
- Searched PubMed, Embase, Web of Science and Cochrane Library to 13 February 2022
Pooled result
ICH recurrence
Hazard ratio
0.85
95% CI 0.57–1.25
P = 0.41
OAC vs No anticoagulants
HR 0.85 (95% CI 0.57–1.25); P = 0.41
As reported in the abstract
Safety
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Major bleeding | 1.66 (1.20–2.30) | P < 0.01 | |
| 0.512Hazard ratio (log scale) |
Original publication
Anticoagulant in atrial fibrillation patients with prior intracranial haemorrhage: a meta-analysis. Heart. Published 15 June 2023. doi:10.
Summarised from the published abstract; every number is checked against it